Efficacy and safety of sequential transarterial embolization and cryoablation of renal masses greater than 3 cm.

Abstract

To determine the efficacy and safety of sequential transarterial embolization and percutaneous cryoablation of renal masses > 3 cm.Forty six patients underwent sequential transarterial embolization and percutaneous cryoablation of a renal mass > 3 cm (31 patients with mass > 4 cm) at two tertiary academic medical centers between 2014 and 2024. Primary efficacy was defined as the percentage of target tumors with no evidence of residual enhancement following the initial procedure. Secondary efficacy included tumors that underwent successful repeat ablation after identifying local tumor progression. Adverse events were classified according to the Society of Interventional Radiology criteria. Kaplan-Meier survival analysis was utilized to determine progression-free survival rates.The median tumor diameter was 4.5 cm (IQR 3.5-5.3 cm). Primary and secondary efficacy rates for T1a lesions were 93% and 100%, respectively. Primary and secondary efficacy rates for T1b lesions were 81% and 87%, respectively. The 1-year and 2-year progression-free survival rates were 94% and 87%, respectively, after a median imaging follow-up period over 1.6 years (IQR 0.9-3.1). The overall adverse event rate was 13% (6/46) and the severe adverse event rate was 4% (2/46). Both severe adverse events were related to post-procedural hemorrhage.Sequential transarterial embolization and percutaneous cryoablation is a technically feasible and effective treatment option with a low severe adverse event rate for renal masses > 3 cm.

View details for DOI 10.1016/j.urolonc.2025.11.018

View details for PubMedID 41423375